CD8A and neoplasm: For instance, tumor-associated macrophages and regulatory T cells are associated with pro-tumor functions [10–12], whereas tumor-infiltrating lymphocytes and CD8+ T effector cells have been associated with improved clinical outcomes and better response to immunotherapy [13–15].